6:22 PM
May 10, 2012
 |  BC Extra  |  Clinical News

Bisphosphonate uncertainties linger at FDA

Eight months after an FDA panel recommended clarifying the duration of use in labels of bisphosphonates for osteoporosis, the agency said further investigation on the benefit-risk profile is still needed to determine the best long-term treatment regimen. In a perspective paper published in the New England Journal...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >